1. "Lymphoma"
Formats
  1. Meeting Abstract (1340)
  2. Journal Article (1048)
  3. Book Section (63)
  4. Review (63)
  5. Editorial (37)
  6. Research Letter (35)
  7. Guidelines (18)
  8. Conference Paper (15)
  9. Correspondence (11)
  10. Miscellaneous (5)
  11. Book Whole (4)
Groups
  1. Center for Hematologic Malignancies (2639)
  2. Department of Medicine (2639)
  3. Hematologic Malignancies, Division of (2639)
  4. Lymphoma (2639)
  5. Population Sciences Research Program (720)
  6. Survivorship Research (633)

More Groups

People
  1. Andrew Zelenetz (767)
  2. Steven Horwitz (645)
  3. Maria Palomba (415)
  4. David Straus (356)
  5. Ariela Noy (351)
  6. Alison Moskowitz (339)

More People

Years
  1. 2025 (28)
  2. 2024 (100)
  3. 2023 (180)
  4. 2022 (170)
  5. 2021 (171)
  6. 2020 (170)

More Years

Publications
  1. Blood (833)
  2. Journal of Clinical Oncology (274)
  3. Hematological Oncology (110)
  4. Leukemia and Lymphoma (81)
  5. British Journal of Haematology (79)
  6. Haematologica (71)

More Publications

Publishers
  1. American Society of Hematology (898)
  2. American Society of Clinical Oncology (290)
  3. Elsevier Inc. (187)
  4. Wiley Blackwell (173)
  5. John Wiley & Sons (95)
  6. Nature Publishing Group (92)

More Publishers

Results (2639)


Citation style sort is year ascending, and then by author or title. Author ascending is default.
  • Efficacy of idelalisib in CLL subpopulations harboring del(17p) and other adverse prognostic factors: Results from a phase 3, randomized, double-blind, placebo-controlled trial
    Meeting Abstract

    Stilgenbauer, S.; Hallek, M. J.; Coutre, S. E.; Furman, R. R.; Cheson, B. D.; Pagel, J. M.; Hillmen, P.; Barrientos, J. C.; Zelenetz, A. D.; Kipps, T. J.; more...
    Oncology Research and Treatment (2014)

    Fulltext@MSK | Save
  • Efficacy of idelalisib in Cll subpopulations harboring del(17p) and other adverse prognostic factors: Results from a phase 3, randomized, double-blind, placebo-controlled trial
    Meeting Abstract

    Stilgenbauer, S.; Coutre, S. E.; Furman, R. R.; Cheson, B. D.; Pagel, J. M.; Hillmen, P.; Barrientos, J. C.; Zelenetz, A. D.; Kipps, T. J.; Flinn, I. W.; more...
    Haematologica (2014)

    Fulltext@MSK | Save
  • Pre-treatment with idelalisib markedly reduces Rituximab infusion-related reactions and infusion interruptions in patients with CLL
    Meeting Abstract

    Hillmen, P.; Furman, R. R.; Coutre, S. E.; Sharman, J. P.; Pagel, J. M.; Barrientos, J. C.; Zelenetz, A. D.; Kipps, T. J.; Flinn, I.; Ghia, P.; more...
    Haematologica (2014)

    Fulltext@MSK | Save
  • Pre-treatment with Idelalisib markedly reduces Rituximab infusion-related reactions and infusion interruptions in patients with CLL
    Meeting Abstract

    Hallek, M.; Hillmen, P.; Furman, R. R.; Coutre, S. E.; Sharman, J. P.; Pagel, J. M.; Barrientos, J. C.; Zelenetz, A. D.; Kipps, T. J.; Flinn, I. W.; more...
    Oncology Research and Treatment (2014)

    Fulltext@MSK | Save
  • 2nd analysis of a phase 3, randomized, double-blind, placebo-controlled study evaluating the efficacy and safety of Idelalisib and Rituximab for previously treated patients with chronic lymphocytic leukemia
    Meeting Abstract

    Hallek, M.; Coutre, S. E.; Furman, R. R.; Sharman, J. P.; Cheson, B. D.; Pagel, J. M.; Hillmen, P.; Barrientos, J. C.; Zelenetz, A. D.; Kipps, T. J.; more...
    Oncology Research and Treatment (2014)

    Fulltext@MSK | Save
  • Effect of idelalisib/rituximab combination treatment of relapsed cll on the bcr signaling-related chemokines ccl3 and ccl4: Data from a phase 3, randomized, double-blind, placebo-controlled trial
    Meeting Abstract

    Ghia, P.; Coutre, S. E.; Furman, R. R.; Cheson, B. D.; Pagel, J. M.; Hillmen, P.; Barrientos, J. C.; Zelenetz, A. D.; Kipps, T. J.; Flinn, I. W.; more...
    Haematologica (2014)

    Fulltext@MSK | Save
  • Health-related quality of life impact of idelalisib (idela) in patients with relapsed chronic lymphocytic leukemia (cll): Phase 3 results
    Meeting Abstract

    Eradat, H. A.; Ghia, P.; O'Brien, S. M.; Hillmen, P.; Furman, R. R.; Coutre, S. E.; Sharman, J. P.; Cheson, B. D.; Pagel, J. M.; Barrientos, J. C.; more...
    Haematologica (2014)

    Fulltext@MSK | Save
  • Second interim analysis of a phase 3 study evaluating idelalisib and rituximab for relapsed cll
    Meeting Abstract

    Coutre, S. E.; Furman, R. R.; Sharman, J. P.; Cheson, B. D.; Pagel, J. M.; Hillmen, P.; Barrientos, J. C.; Zelenetz, A. D.; Kipps, T. J.; Flinn, I. W.; more...
    Haematologica (2014)

    Fulltext@MSK | Save
  • Cutaneous hemophagocytosis after alemtuzumab injection in a patient with Sézary syndrome
    Journal Article

    Jawed, S. I.; Busam, K.; Wang, X.; Horwitz, S.; Querfeld, C.
    JAMA Dermatology (2014)

    Fulltext@MSK | Save
  • Precision therapy for lymphoma - Current state and future directions
    Journal Article

    Intlekofer, A. M.; Younes, A.
    Nature Reviews Clinical Oncology (2014)

    Fulltext@MSK | Save